Specific Antiviral Drugs for COVID 19 Market Report 2026

The specific antiviral drugs for COVID-19 market size has grown rapidly in recent years. It will grow from $15.23 billion in 2025 to $17.83 billion in 2026 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to rapid spread of COVID-19, emergency use authorizations, reliance on traditional antiviral drug classes, limited global production capacity, high hospitalization rates.

The specific antiviral drugs for COVID-19 market size is expected to see rapid growth in the next few years. It will grow to $33.17 billion in 2030 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to development of next-generation antiviral drugs, increased public-private partnerships, rising preventive treatment adoption, expansion of combination therapies, integration of personalized medicine approaches. Major trends in the forecast period include rising investment in COVID-19 antiviral drug development, increasing adoption of oral antiviral tablets, growth in monoclonal antibody therapies, expansion of hospital and retail distribution channels, focus on targeted treatment for hospitalized and high-risk patients.

The growing number of COVID-19 cases is anticipated to drive the expansion of the specific antiviral drugs for the COVID-19 market in the coming years. COVID-19 cases refer to individuals who have tested positive for infection with the SARS-CoV-2 virus, the causative agent of COVID-19. The increase in COVID-19 cases is largely attributed to the emergence of new viral variants that demonstrate higher transmissibility and partial ability to evade immunity gained from vaccination or prior infection. Specific antiviral drugs for COVID-19 support disease management by lowering illness severity and shortening recovery time, thereby improving patient outcomes and reducing the overall healthcare burden associated with COVID-19. For example, in May 2025, according to the World Health Organization, a Switzerland-based global public health agency, the test positivity rate in the Eastern Mediterranean region rose sharply from 4% to 17% in early 2025, exceeding levels recorded during the same period in 2024. Therefore, the increasing number of COVID-19 cases is driving the growth of the specific antiviral drugs for the COVID-19 market.

Major companies operating in the specific antiviral drugs for the COVID-19 market are concentrating on the development of innovative treatment options, such as oral antiviral therapies, to improve treatment accessibility and clinical effectiveness. Oral antiviral therapies are medications administered by mouth that work by inhibiting viral replication, offering a convenient and effective approach to treating COVID-19. For instance, in March 2024, Shionogi & Co., a Japan-based pharmaceutical company, launched Xocova and received full standard approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its antiviral drug ensitrelvir. The therapy also provides post-exposure prophylaxis by significantly lowering the risk of symptomatic COVID-19 among exposed individuals and reducing symptom duration while maintaining a favorable safety profile.

In July 2024, GSK plc, a UK-based pharmaceutical company, partnered with CureVac to jointly develop and commercialize next-generation mRNA vaccines targeting COVID-19 and influenza. This collaboration aims to advance innovative mRNA-based vaccines to enhance global public health outcomes. CureVac N.V. is a Germany-based biotechnology company specializing in the development of messenger RNA (mRNA)-based therapies.

Major companies operating in the specific antiviral drugs for COVID-19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

North America was the largest region in the specific antiviral drugs for COVID-19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for COVID-19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the specific antiviral drugs for COVID-19 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the specific antiviral drugs for COVID-19 market by increasing the cost of imported active pharmaceutical ingredients (APIs) and raw materials used in tablet and injection formulations. Segments such as nucleoside analogues and monoclonal antibodies are particularly impacted, with regions like Asia-Pacific, including China and India, facing significant import duties. While this raises production costs and can delay supply, tariffs have also encouraged local API production, investment in domestic manufacturing, and innovation in drug formulation strategies.

The specific antiviral drugs for COVID-19 market research report is one of a series of new reports that provides specific antiviral drugs for COVID-19 market statistics, including specific antiviral drugs for COVID-19 industry global market size, regional shares, competitors with a specific antiviral drugs for COVID-19 market share, detailed specific antiviral drugs for COVID-19 market segments, market trends and opportunities, and any further data you may need to thrive in the specific antiviral drugs for COVID-19 industry. This specific antiviral drugs for COVID-19 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Specific antiviral drugs for COVID-19 are medications developed to directly target and suppress the replication or activity of the SARS-CoV-2 virus, which is responsible for COVID-19. These drugs help lessen the severity and shorten the duration of infection by disrupting key viral processes such as entry into host cells, replication, or viral assembly.

The main forms of specific antiviral drugs for COVID-19 include tablets and injectable formulations. Tablets are solid dosage forms containing an exact amount of active pharmaceutical ingredients along with excipients, compressed into small, typically flat or oval shapes. These antiviral medications are used for hospitalized patients, non-hospitalized patients, and for preventive treatment. The drug classes include nucleoside analogues, protease inhibitors, RNA polymerase inhibitors, entry inhibitors, and monoclonal antibodies. They are administered through various routes such as oral, intravenous, subcutaneous, and inhalation, and are distributed through channels including hospital pharmacies, retail pharmacies, and other distribution outlets.

The specific antiviral drugs for COVID-19 market consists of sales of host-directed antivirals, immunomodulators, fusion inhibitors, helicase inhibitors, and tmprss2 inhibitors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.